Sept 2011: UK study on new CMV treatment gets funding

     
At the moment the main treatment available for congenital CMV  is Ganciclovir. However it is an invasive treatment for a newborn baby (it is administered via intraveinous drip), and in some cases it can cause adverse effects. Also, Ganciclovir treatment must be started before a baby is 4 weeks old, leaving a very small window  of opportunity to combat the possible effects of CMV, especially if it is not diagnosed immediately at birth. [singlepic id=59 w=250 float=left]A new study has just been awarded funding to test a less invasive oral antiviral called Valganciclovir. The study will  test 6 weeks of valgancyclovir treatment in infants aged 1-18 months old, significantly increasing the potential window for treating congenital CMV. Please email info@cmvaction.org.uk if you are interested in finding out more. &;

Tags: 

  • news
     

Our Stories

January 2015 Our names are Dawn Bean, 43 and Daniel Hunt, 37. We are lucky to be the proud parents of Joseph (Joey) Hunt, 2 (02.01.2015) who has a super sister, Daisy, 14 and a brilliant... Read more
Written by her grandmother Jan – now a Trustee of CMV Action. 16th July 2012. That day changed our lives.   James (my son) and Lucy were expecting their first child, a girl. It... Read more

Latest Events

Reg. charity no: 1171773